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characterize the relationship between immunophenotypic markers
of T cell maturation and functional attributes of T cells, we
optimized an 8-color, 10-parameter cytokine ﬂow cytometry
(CFC) approach and examined PBMC in 3 healthy donors. PBMC
were exposed to stimuli that both bypass and signal through the T
cell receptor (PMA/Ionomycin&em;P:I and staph enterotoxin
B&em;SEB, respectively) and stained with CD45RA and CD27 to
demarcate naı¨ve (N, CD45RACD27), memory (M, CD45RA-
CD27-) and late-memory (LM, CD45RACD27-) CD4 and
CD8 T cells. We assessed the production of effector cytokines
(IL-2, IFN, TNF
 and MIP1) within the three maturation
subsets. Following PMA and SEB stimulation, all maturation sub-
sets (N, M and LM) of CD4 and CD8 T cells produced IFN.
TNF
 production was similarly distributed after P:I stimulation.
However, after SEB stimulation, LM CD4 and CD8 cells
produced only 2.5% and 8.5% of total TNF
, respectively. Pro-
duction of IL-2 and MIP1- was much more skewed, with LM
cells contributing little to total IL-2 production after stimulation
with P:I (0.2% of total, CD4; 0%, CD8) or SEB (CD4, 2.1%;
CD8, 2.8%). While LM cells produced little or no IL-2, they
produced the bulk of MIP1- following stimulation with P:I
(96.5%, CD4; 84.8%, CD8) or SEB (97.5%, CD4; 70.7%, CD8).
Co-production of IL-2 and IFN in T cells has recently been
postulated to be important for protective immunity. Importantly,
no IL-2IFN cells were seen in the LM compartment follow-
ing P:I stimulation (CD4 Distribution: 8.9% N, 91.1% M, 0%
LM; CD8: 15.7% N, 84.3% M, 0% LM). Results following SEB
stimulation were similar (CD4: 3.3% N, 94.9% M, 1.8% LM;
CD8: 12.2% N, 87.8% M, 0% LM). Overall, these results suggest
that: 1) T cell maturation stage does correlate strongly with func-
tional capacity; 2) Nearly all IL-2 production occurs in N and M
cells; 3) LM cells produce little or no IL-2; but most of total
MIP-1; 4) IL-2/IFN co-production is absent in LM cells, per-
haps suggesting why late-stage skewing after SCT is associated
with functional T cell impairment; and 5) Maturation stage appears
to be more closely associated with functional status than CD4 or
CD8 lineage. These results may have important implications for
clinical studies of post-SCT immune recovery and GVHD.
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The current study evaluated the clinical efﬁcacy of long-term low
dose acyclovir (ACV) prophylaxis for varicella-zoster virus (VZV)
after allogeneic peripheral blood stem cell transplantation (PB-
SCT). The clinical data of transplant records since 2000 has been
retrospectively retrieved from 2 transplant centers. Princess Mar-
garet Hospital (PMH) group used ACV 400mg/day po till day 28,
whlie Kyungpook National University Hospital (KNUH) group
adopted ACV 800-1200mg/day po till at least 6-9 months. PMH
group (n193) was prone to more lymphoproliferative disorder,
and more TBI-based regimen, while KNUH group (n79) was
prone to more mismatched PBSCT, and high risk acute leukemia
patients. Out of 193 pts in PMH group, 26 patients (13.5%)
received long-term ACV prophylaxis, while 73 patients (92.4%) in
KNUH group received. Overall survival (OS) showed a trend of
favorable survival toward PMH group (p0.227), while no differ-
ence of OS between 2 groups was noted conﬁned to HLA-identical
sibling PBSCT (p0.793). In PMH group, 42 cases (22%) devel-
oped VZV infection presented as localized (n36) or disseminated
involvement (n6), while 6 cases (8%) of VZV infection was noted
in KNUH group presenting as localized involvement (n6;
p0.005). With median 26.5 months of follow-up among survi-
vors, the incidences of VZV infection at 1 and 2 years were
19.23.3 and 27.04.1% in PMH, and 3.42.4 and 8.64.3% in
KNUH group, respectively (p0.002). When conﬁned to HLA-
identical sibling transplants, the incidence of VZV infection at 2
years was 26.44.3% at PMH, and 8.84.4% at KNUH
(p0.004). Taking into account for other potential risk factors for
VZV infection in multivariate analysis, the use of long-term ACV
as a time-dependent covariate was identiﬁed as the only indepen-
dent risk factor for VZV infection after allogeneic PBSCT
(p0.001, HR 0.130, 95% C.I. [0.0400.425]). Long-term use of
ACV seemed to be protective from VZV infection after allogeneic
PBSCT. Further prospective study on the role of low dose ACV is
strongly warranted in allogeneic PBSCT setting.
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The incidence of graft rejection is increasing in association
with an increased use of non-myeloablative conditioning regi-
men, alternative donors, and cord blood transplantation. We
investigated a role of host T cells in graft rejection following
non-myeloablative conditioning bone marrow transplantation
(BMT) in an MHC mismatched B6D2F1 (H-2b/d) into B6
(H-2b) mouse model of BMT, where host T cells can be acti-
vated to kill donor cells. BMT following 6 Gy, 7Gy, and 10Gy
total body irradiation (TBI) resulted in a primary graft rejection,
secondary graft rejection, and engraftment of donor cells, re-
spectively. Interestingly, expansion of host T cells is observed in
the bone marrow and spleen 2 weeks after BMT, followed by a
brisk increase in number of host T cells in peripheral blood one
week later. CD8 T cells isolated from bone marrow produced
interferon-gamma and lysed donor cells. We then examined
whether donor-derived dendritic cells (DCs) play a role in this
rejection, using transgenic mice carrying diphtheria toxin re-
ceptor (DTR) under the control of the CD11c promoter, which
allows selective ablation of CD11c DCs by injection of diph-
theria toxin (DTx), as donors. In the recipients conditioned with
6Gy TBI, depletion of donor-derived DCs with DTx injection
reduced the host T cell-expansion and leads to transient mixed
chimerism in contrast to primary graft rejection in controls. We
then tested whether such an early recovery of host T cells could
be predictive of the graft rejection in 7 adult recipients of
non-myeloablative cord blood transplantation. Three week
post-transplant, an overshoot of host T cells was observed in 2
patients who experienced rejection, but in none of 5 patients
with engraftment. These results suggest that residual host T
cells are associated with graft rejection and an early recovery of
host T cells may be predictive of graft rejection after non-
myloablative allogeneic hematopoietic stem cell transplantation.
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DLI are frequently employed after nonmyeloablative (mini)
allogeneic marrow transplant (allo-BMT) to enhance chimer-
ism. To ensure the ready availability of cells for DLI we cryo-
preserved CD3 cells from mobilized allo-BMT donors. We
report here the safety and efﬁcacy of infusing cryopreserved
CD3 T cells for DLI (c-DLI) from G-CSF mobilized allo-
PBSC donors and the overall clinical utility of c-DLI. Methods:
Graded doses of CD3 donor T cells from allo-PBSC (2 bags
of 10  106 & 2 of 50  106/kg pt wgt) were cryopreserved in
10% DMSO using a controlled rate freezer and stored in vapor-
phase liquid nitrogen until use. We reviewed patients (pts) who
received allo-BMT for hematologic malignancy from 1/03 to
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